Recent News

• 03.10.2025 - UroGen Pharma Q4 2024 Earnings Call
• 03.10.2025 - UroGen Pharma Q4 2024 Earnings Call
• 03.10.2025 - UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102
• 03.10.2025 - UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102
• 03.07.2025 - UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 03.07.2025 - UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 03.03.2025 - TD Cowen 45th Annual Health Care Conference
• 03.03.2025 - TD Cowen 45th Annual Health Care Conference
• 03.03.2025 - TD Cowen 45th Annual Health Care Conference
• 03.03.2025 - TD Cowen 45th Annual Health Care Conference

Recent Filings

• 03.10.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.10.2025 - 8-K Current report
• 03.10.2025 - EX-99.1 EX-99.1